Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GLAXF) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to 30.34%.

  • Gsk's EBIT Margin rose 279800.0% to 30.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.41%, marking a year-over-year increase of 53900.0%. This contributed to the annual value of 12.82% for FY2024, which is 94200.0% down from last year.
  • As of Q3 2025, Gsk's EBIT Margin stood at 30.34%, which was up 279800.0% from 25.33% recorded in Q2 2025.
  • Gsk's 5-year EBIT Margin high stood at 61.57% for Q4 2021, and its period low was 2.36% during Q3 2024.
  • Over the past 5 years, Gsk's median EBIT Margin value was 23.9% (recorded in 2022), while the average stood at 25.11%.
  • As far as peak fluctuations go, Gsk's EBIT Margin tumbled by -376800bps in 2022, and later surged by 279800bps in 2025.
  • Gsk's EBIT Margin (Quarter) stood at 61.57% in 2021, then plummeted by -61bps to 23.9% in 2022, then grew by 25bps to 29.89% in 2023, then crashed by -31bps to 20.57% in 2024, then soared by 48bps to 30.34% in 2025.
  • Its EBIT Margin was 30.34% in Q3 2025, compared to 25.33% in Q2 2025 and 29.48% in Q1 2025.